Analyst Terence Flynn from Morgan Stanley maintained a Hold rating on Gilead Sciences (GILD – Research Report) and keeping the price ...

The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.

Gilead Sciences, Inc. (Nasdaq: GILD) today announced new research to be presented at The Liver Meeting® 2024, hosted by the ...

Leerink Partnrs upgraded shares of Gilead Sciences (NASDAQ:GILD – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Monday, Zacks.com reports. A number ...

The withdrawal of the FDA accelerated approval for locally advanced or metastatic urothelial carcinoma, a type of bladder ...

Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...

Gilead Sciences, Inc. (GILD), headquartered in Foster City, California, is a global biopharmaceutical leader known for its ...

Morgan Stanley notes that Gilead (GILD) and Arcellx’s (ACLX) anito-cel, a BCMA-directed CAR-T therapy in development for relapsed / ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical, Co. Ltd. (Otsuka), today announce positive topline interim data from the ongoing Phase 3 clinical trial of ...

Neural Concept, the leading end-to-end 3D AI platform that transforms product design with Engineering Intelligence, has announced the opening of a new office in the United States, located in the New ...

The collaboration outlines plans for multiple in vivo studies, designed to test opaganib as a potential medical countermeasure to treat phosgene i ...

The US Court of Appeals for the Federal Circuit issued its opinion in Allergan USA, Inc. v. MSN Laboratories Private Ltd., No ...